Cohort Study | Analysis of Rituximab use and COVID-19 hospitalization or death in patients with multiple sclerosis

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis – JAMA Network Open

Commentary on Twitter

Patients with MS on rituximab vaccinated for #COVID19 6 months before or after their last infusion had a much lower risk of COVID hospitalization – 1.4 vs 3.6 per 100 among unvaccinated people. https://t.co/am6hdSidMT

— JAMA Network Open (@JAMANetworkOpen) December 28, 2022